Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4735-4738

  Saksawad, Rachanee ^a   Likitnukul, Sasithorn ^a   Warachit, Boonyarat ^b   Hanvivatvong, Orrawadee ^a   Poovorawan, Yong ^a   Puripokai, Panitchaya ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b HATYAI HOSPITAL   (Thailand)

Author keywords

Hepatitis A vaccine; HIV infected children; Immunogenicity; Pediatric dose; Safety; Virosome

Indexed keywords

HEPATITIS A VACCINE; UNCLASSIFIED DRUG; VIROSOMAL HEPATITIS A VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THAILAND; VACCINATION;

EID: 79960627958     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.091     Document Type: Article

References (22)

1. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-10.
2. Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1996;14:982-6.
3. Clarke PD, Adams P, Ibanez R, Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminum-adsorbed hepatitis A vaccine in UK travellers. Travel Med Infect Dis 2006;4:313-8.
4. Usonis V, Bakasenas V, Volentelis R, Katiliene G, Vidzeniene D, Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®). Vaccine 2003;21:4588-92.
5. Riedemann S, Reinhardt G, Ibarra H, Frosner G. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile. Acta Paediatr 2004;93:412-4.
6. Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frösner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003;188:671-7.
7. Van der Wielen M, Vertroyen A, Froesner G, Ibánez R, Hunt M, Herzog C, et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr Infect Dis J 2007;26:705-10.
8. Gouvea AF, De Moraes-Pinto MI, Ono E, Dinelli MIS, Machado DM, Weckx LY, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis 2005;41:544-8.
9. Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006;193:302-11.
10. Loutan L, Bovier O, Herzog C. Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients. Vaccine 2007;25:6310-2.
11. Chatproedprai S, Chongsrisawat V, Chatchatee P, Theamboonlers A, Yoocharoen P, Warinsathien P, et al. Declining trend in the seroprevalence of infection with hepatitis A virus in Thailand. Ann Trop Med Parasitol 2007;101:61-8.
12. Barameechai K, Sa-nguanmoo P, Suwannakarn K, Thongmee C, Payungporn S, Chongsrisawat V, et al. Molecular characterisation of the hepatitis A virus circulating in the 2001-2005 outbreaks in Thailand. Ann Trop Med Parasitol 2008;102:247-57.
13. Pancharoen C, Mekmullica J, Thisyakorn U, Kasempimolporn S, Wilde H, Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 2005;41:1537-40.
14. Siberry GK, Coller RJ, Henkle E, Kiefner C, Joyner M, Rogers J, et al. Antibody response to hepatitis A immunization among human immunodeficiency virusinfected children adolescents. Pediatr Infect Dis J 2008;27:465-8.
15. Weinberg A, Huang S, Fenton T, Patterson-Bartlett J, Gona P, Read JS, et al. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J AIDS 2009;52:17-24.
16. Wallace MR, Brondt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207-13.
17. Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327-31.
18. Tasker SA, Wallace MR. Vaccination in HIV-infected patients. Curr Infect Dis Rep 2000;2:247-56.
19. Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 2005;23:2424-9.
20. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis A vaccine. Infection 2004;32:149-52.
21. Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-71.
22. Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, et al. Predicted 30-year protection after vaccination with an inactivated virosomal hepatitis A vaccine. J Med Virol 2010;82:1629-34.